why choose us

First received: June 07, 2023

Clinical Trial: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Gastrointestinal Stromal Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.

Read more